Lyfegen Raises $8M for Value-Based Contracting for High-Cost Drugs
HIT Consultant
SEPTEMBER 20, 2022
Currently, less than 2% of the health insurance population requiring specialty drugs is responsible for 51% of drug spending. With Lyfegen’s patent-pending platform, health insurances & hospitals can implement and scale value-based healthcare, improving access to treatments, patient health outcomes and affordability.
Let's personalize your content